Using a new human milk fortifier to optimize human milk feeding among very preterm and/or very low birth weight infants: a multicenter study in China

Table 4 Feeding tolerance and morbidities during hospitalization in the nHMF and cHMF group

Feeding tolerance and morbidity	nHMF group (n = 95)	cHMF group (n = 148)	OR/HR (95%CI)	P-Value
Feeding intolerance, n (%)	5 (5.2)	8 (5.4)	1.12(0.26, 4.8)	0.87
Necrotizing enterocolitis ≥ 2 stage, n (%)	1(1.05)	2(1.35)	0.67(0.04, 10.4)	0.77
Bronchopulmonary dysplasia^*, n (%)	30(31.9)	61(41.2)	0.88(0.44, 1.78)	0.73
Retinopathy of prematurity ≥ 2 stage, n (%)	10(13.6)	37(25.0)	2.10 (0.92, 4.76)	0.07
Culture-confirmed sepsis, n (%)	3(3.1)	7(4.7)	2.38(0.76, 6.32)	0.14
Time to achieve full enteral feeding, days	13.5(10, 21)	17(12, 23)	0.67(0.49, 0.92)	0.01
Time to full-strength fortification, days	16(12, 23)	22.5(16, 30)	1.12(0.84, 1.49)	0.46

Median and inter-quartile range (IQR) was used to describe continuous variables; Multiple logistic regression models were used in compare the difference of feeding intolerance incidences and morbidities. Cox regression models were used in compare the difference of time to achieve full enteral feeding and time to full-strength fortification. Gestational age, sex, birth weight, age at start of HMF usage were adjusted as covariates
^* The number of infants in nHMF group was 94 when calculated the incidence of bronchopulmonary dysplasia, because of one infant were dead
nHMF, new human milk fortifier; cHMF, control human milk fortifier

ISSN: 1471-2431